No Prescription |
 |
 | ||
|
Floraquin Diquinol |
|
| ||
No Prescription » Prescription Drugs 8 » Floraquin Diquinol INDICATIONS:Trichomonas vaginitis monilial vaginitis non-specific and mixed vaginitis.DOSAGE AND DIRECTIONS FOR USE:Two tablets daily inserted high in the vagina before retiring for two or more menstrual cycles. The tablets should be moistened with water before insertion into the vagina. Warm acid douches may be taken as prescribed by the physician or when necessary or desired for hygienic purposes.An applicator is provided to assist correct placement. The importance of personal hygiene is in no way diminished during Floraquin therapy and the presence of vaginal discharge indicates that a sanitary pad should be worn. Buy Floraquin Diquinol and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About Floraquin Diquinol: Product Type: Prescription Drugs 8 Floraquin ( Diquinol Yodoxin Generic di-iodohydroxyquinoline ) Floraquin (Diquinol Yodoxin Generic di-iodohydroxyquinoline) Diquinol Yodoxin Generic di-iodohydroxyquinoline 100mg 25 Vaginal Tablets 50 Vaginal Tablets 100 Vaginal Tablets Diquinol Yodoxin Generic di-iodohydroxyquinoline Floraquin
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
